Literature DB >> 25716838

Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke.

Masahito Kawabori1, Rachid Kacimi2, Tiina Kauppinen3, Cyrus Calosing1, Jong Youl Kim1, Christine L Hsieh2, Mary C Nakamura1, Midori A Yenari4.   

Abstract

Clearing cellular debris after brain injury represents an important mechanism in regaining tissue homeostasis and promoting functional recovery. Triggering receptor expressed on myeloid cells-2 (TREM2) is a newly identified receptor expressed on microglia and is thought to phagocytose damaged brain cells. The precise role of TREM2 during ischemic stroke has not been fully understood. We explore TREM2 in both in vitro and in vivo stroke models and identify a potential endogenous TREM2 ligand. TREM2 knockdown in microglia reduced microglial activation to an amoeboid phenotype and decreased the phagocytosis of injured neurons. Phagocytosis and infarcted brain tissue resorption was reduced in TREM2 knock-out (KO) mice compared with wild-type (WT) mice. TREM2 KO mice also had worsened neurological recovery and decreased viable brain tissue in the ipsilateral hemisphere. The numbers of activated microglia and phagocytes in TREM2 KO mice were decreased compared with WT mice, and foamy macrophages were nearly absent in the TREM2 KO mice. Postischemia, TREM2 was highly expressed on microglia and TREM2-Fc fusion protein (used as a probe to identify potential TREM2 binding partners) bound to an unknown TREM2 ligand that colocalized to neurons. Oxygen glucose deprivation-exposed neuronal media, or cellular fractions containing nuclei or purified DNA, but not cytosolic fractions, stimulated signaling through TREM2. TREM2-Fc fusion protein pulled down nucleic acids from ischemic brain lysate. These findings establish the relevance of TREM2 in the phagocytosis of the infarcted brain and emphasize its role in influencing neurological outcomes following stroke. Further, nucleic acids may be one potential ligand of TREM2 in brain ischemia.
Copyright © 2015 the authors 0270-6474/15/353384-13$15.00/0.

Entities:  

Keywords:  ischemia; neuroprotection; permanent ischemia; phagocytosis; stroke; triggering receptor expressed on myeloid cells-2

Mesh:

Substances:

Year:  2015        PMID: 25716838      PMCID: PMC4339351          DOI: 10.1523/JNEUROSCI.2620-14.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family.

Authors:  Y Numasawa; C Yamaura; S Ishihara; S Shintani; M Yamazaki; H Tabunoki; J-I Satoh
Journal:  Eur J Neurol       Date:  2010-12-22       Impact factor: 6.089

Review 2.  The inflammatory response in stroke.

Authors:  Qing Wang; Xian Nan Tang; Midori A Yenari
Journal:  J Neuroimmunol       Date:  2006-12-26       Impact factor: 3.478

3.  Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro.

Authors:  Midori A Yenari; Lijun Xu; Xian Nan Tang; Yanli Qiao; Rona G Giffard
Journal:  Stroke       Date:  2006-02-23       Impact factor: 7.914

4.  TREM2 and neurodegenerative disease.

Authors:  Rita Guerreiro; John Hardy
Journal:  N Engl J Med       Date:  2013-10-17       Impact factor: 91.245

5.  Differential neuroprotection from human heat shock protein 70 overexpression in in vitro and in vivo models of ischemia and ischemia-like conditions.

Authors:  J E Lee; M A Yenari; G H Sun; L Xu; M R Emond; D Cheng; G K Steinberg; R G Giffard
Journal:  Exp Neurol       Date:  2001-07       Impact factor: 5.330

6.  Transplanted bone marrow stromal cells protect neurovascular units and ameliorate brain damage in stroke-prone spontaneously hypertensive rats.

Authors:  Masaki Ito; Satoshi Kuroda; Taku Sugiyama; Katsuhiko Maruichi; Masahito Kawabori; Naoki Nakayama; Kiyohiro Houkin; Yoshinobu Iwasaki
Journal:  Neuropathology       Date:  2012-01-12       Impact factor: 1.906

7.  Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation.

Authors:  Gregory J del Zoppo; Harald Frankowski; Yu-Huan Gu; Takashi Osada; Masato Kanazawa; Richard Milner; Xiaoyun Wang; Naohisa Hosomi; Takuma Mabuchi; James A Koziol
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-22       Impact factor: 6.200

8.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

9.  Microglia cells protect neurons by direct engulfment of invading neutrophil granulocytes: a new mechanism of CNS immune privilege.

Authors:  Jens Neumann; Steven Sauerzweig; Raik Rönicke; Frank Gunzer; Klaus Dinkel; Oliver Ullrich; Matthias Gunzer; Klaus G Reymann
Journal:  J Neurosci       Date:  2008-06-04       Impact factor: 6.167

10.  Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia.

Authors:  Xian Nan Tang; Qing Wang; Maya A Koike; Danye Cheng; Michael L Goris; Francis G Blankenberg; Midori A Yenari
Journal:  J Nucl Med       Date:  2007-10-17       Impact factor: 10.057

View more
  124 in total

Review 1.  Regulation of microglial activation in stroke.

Authors:  Shou-Cai Zhao; Ling-Song Ma; Zhao-Hu Chu; Heng Xu; Wen-Qian Wu; Fudong Liu
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

2.  Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity.

Authors:  Qingkun Liu; Emily M Johnson; Rachel K Lam; Qian Wang; Hong Bo Ye; Edward N Wilson; Paras S Minhas; Ling Liu; Michelle S Swarovski; Stephanie Tran; Jing Wang; Swapnil S Mehta; Xi Yang; Joshua D Rabinowitz; Samuel S Yang; Mehrdad Shamloo; Christoph Mueller; Michelle L James; Katrin I Andreasson
Journal:  Nat Immunol       Date:  2019-07-01       Impact factor: 25.606

Review 3.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

Review 4.  Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

Authors:  Yuetiva Deming; Zeran Li; Bruno A Benitez; Carlos Cruchaga
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

Review 5.  Glia-immune interactions post-ischemic stroke and potential therapies.

Authors:  Jessica Hersh; Shao-Hua Yang
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-11

6.  Intranasal wnt3a Attenuates Neuronal Apoptosis through Frz1/PIWIL1a/FOXM1 Pathway in MCAO Rats.

Authors:  Nathanael Matei; Justin Camara; Devin McBride; Richard Camara; Ningbo Xu; Jiping Tang; John H Zhang
Journal:  J Neurosci       Date:  2018-06-28       Impact factor: 6.167

7.  β-Catenin Pathway Is Involved in TREM2-Mediated Microglial Survival.

Authors:  Shadaan Zulfiqar; Gaye Tanriöver
Journal:  J Neurosci       Date:  2017-07-26       Impact factor: 6.167

8.  Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease.

Authors:  Taylor R Jay; Anna M Hirsch; Margaret L Broihier; Crystal M Miller; Lee E Neilson; Richard M Ransohoff; Bruce T Lamb; Gary E Landreth
Journal:  J Neurosci       Date:  2017-01-18       Impact factor: 6.167

Review 9.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

10.  TREM2 deficiency aggravates α-synuclein-induced neurodegeneration and neuroinflammation in Parkinson's disease models.

Authors:  Ying Guo; Xinbing Wei; Hua Yan; Yue Qin; Shaoqi Yan; Jia Liu; Yong Zhao; Fan Jiang; Haiyan Lou
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.